These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 39020428)

  • 21. Analysis of ovarian cancer cell secretome during epithelial to mesenchymal transition reveals a protein signature associated with advanced stages of ovarian tumors.
    Lanfredi GP; Thomé CH; Ferreira GA; Silvestrini VC; Masson AP; Vargas AP; Grassi ML; Poersch A; Candido Dos Reis FJ; Faça VM
    Biochim Biophys Acta Proteins Proteom; 2021 Jun; 1869(6):140623. PubMed ID: 33607274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
    Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
    J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.
    Hu Y; Pan J; Shah P; Ao M; Thomas SN; Liu Y; Chen L; Schnaubelt M; Clark DJ; Rodriguez H; Boja ES; Hiltke T; Kinsinger CR; Rodland KD; Li QK; Qian J; Zhang Z; Chan DW; Zhang H;
    Cell Rep; 2020 Oct; 33(3):108276. PubMed ID: 33086064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model.
    Huang D; Gaul DA; Nan H; Kim J; Fernández FM
    J Proteome Res; 2019 Aug; 18(8):3184-3194. PubMed ID: 31290664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving the cytological diagnosis of high-grade serous carcinoma in ascites with a panel of complementary biomarkers in cell blocks.
    Zhang X; Chen L; Liu Y; Xu Y; Zhang X; Shi Y; Wang C; Zhang PL; Liu Y
    Cytopathology; 2018 Jun; 29(3):247-253. PubMed ID: 29280203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Cancer Biomarker Discovery Using DIA-MS Proteomic Analysis of EVs from Peripheral Blood.
    Espejo C; Lyons B; Woods GM; Wilson R
    Methods Mol Biol; 2023; 2628():127-152. PubMed ID: 36781783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
    Nadaraja S; Schledermann D; Herrstedt J; Østrup O; Ditzel HJ;
    Acta Oncol; 2020 Jan; 59(1):40-47. PubMed ID: 31478407
    [No Abstract]   [Full Text] [Related]  

  • 28. HNF-1β in ovarian carcinomas with serous and clear cell change.
    DeLair D; Han G; Irving JA; Leung S; Ewanowich CA; Longacre TA; Gilks CB; Soslow RA
    Int J Gynecol Pathol; 2013 Nov; 32(6):541-6. PubMed ID: 24071869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of Developmental Endothelial Locus-1 on Circulating Extracellular Vesicles as a Novel Biomarker for Early Breast Cancer Detection.
    Moon PG; Lee JE; Cho YE; Lee SJ; Jung JH; Chae YS; Bae HI; Kim YB; Kim IS; Park HY; Baek MC
    Clin Cancer Res; 2016 Apr; 22(7):1757-66. PubMed ID: 26603257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
    Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
    Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 32. Analysis of ATP7A Expression and Ceruloplasmin Levels as Biomarkers in Patients Undergoing Neoadjuvant Chemotherapy for Advanced High-Grade Serous Ovarian Carcinoma.
    Lukanović D; Polajžer S; Matjašič M; Kobal B; Černe K
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Candidate prognostic biomarkers and prediction models for high-grade serous ovarian cancer from urinary proteomics.
    Ni M; Wan D; Wu J; Gong W; Wang J; Zheng Z
    J Proteomics; 2024 Jul; 304():105234. PubMed ID: 38925351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers.
    Labrie M; De Araujo LOF; Communal L; Mes-Masson AM; St-Pierre Y
    Sci Rep; 2017 Oct; 7(1):13244. PubMed ID: 29038585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
    Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Machine Learning analysis of high-grade serous ovarian cancer proteomic dataset reveals novel candidate biomarkers.
    Farinella F; Merone M; Bacco L; Capirchio A; Ciccozzi M; Caligiore D
    Sci Rep; 2022 Feb; 12(1):3041. PubMed ID: 35197484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive ovarian cancer biomarker detection via an optical nanosensor implant.
    Williams RM; Lee C; Galassi TV; Harvey JD; Leicher R; Sirenko M; Dorso MA; Shah J; Olvera N; Dao F; Levine DA; Heller DA
    Sci Adv; 2018 Apr; 4(4):eaaq1090. PubMed ID: 29675469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
    Salminen L; Nadeem N; Jain S; Grènman S; Carpén O; Hietanen S; Oksa S; Lamminmäki U; Pettersson K; Gidwani K; Huhtinen K; Hynninen J
    Gynecol Oncol; 2020 Mar; 156(3):689-694. PubMed ID: 31889528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer.
    Medrano M; Communal L; Brown KR; Iwanicki M; Normand J; Paterson J; Sircoulomb F; Krzyzanowski P; Novak M; Doodnauth SA; Saiz FS; Cullis J; Al-Awar R; Neel BG; McPherson J; Drapkin R; Ailles L; Mes-Massons AM; Rottapel R
    Cell Rep; 2017 Mar; 18(10):2343-2358. PubMed ID: 28273451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteomics analysis to reveal biological pathways and predictive proteins in the survival of high-grade serous ovarian cancer.
    Xie H; Wang W; Sun F; Deng K; Lu X; Liu H; Zhao W; Zhang Y; Zhou X; Li K; Hou Y
    Sci Rep; 2017 Aug; 7(1):9896. PubMed ID: 28852147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.